Navigation Links
BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Date:11/5/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York.

WHEN: Monday November 10th at 12:00pm (Eastern Time)

WHERE: New York Palace Hotel, New York.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, th
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
5. BioMS Medical to present at UBS Global Life Sciences Conference
6. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
7. BioMS Medical announces its intention to renew a normal course issuer bid
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. BioMS Medical Announces Second Quarter 2008 Results
10. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
11. BioMS Medical to present at BMO Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... NEMA 4 (IP66) Medical Joysticks can be ... have an impermeable molecular barrier protection against bio-hazardous agents. Original Equipment Manufacturers ... healthcare worker safety and reduce financial costs. , CTI Electronics announces a new ...
(Date:6/30/2015)... ... , ... Students and faculty from Beijing City University will ... Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. The ... both universities and is taught on both continents. , “Our alliance with Beijing ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... 22 Accelerated Community Oncology,Research Network (ACORN) ... and clinical trial network, announced today,that it ... of Business Development.,Webb brings a successful record ... has an exceptional background of work in ...
... Symbol: MS, - US$10 million received based on ... pivotal multiple sclerosis trial - EDMONTON, Sept. 22 ... in the treatment of multiple sclerosis (MS), today,announced that ... its,partner, Eli Lilly and Company., The milestone payment ...
... the Effects of Oral Calcitonin, a,combination of Salmon ... CEDAR KNOLLS, N.J., Sept. 22 Emisphere,Technologies, ... Novartis Pharma AG,and Nordic Bioscience have completed recruitment ... and efficacy of an oral formulation of,salmon calcitonin ...
Cached Biology Technology:ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 2ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... deadly 1918 Spanish influenza pandemic is why it struck ... such as St. Louis spared the fate of the ... health measures? What made the difference, according to two ... (NIH), was not only how but also how rapidly ...
... cell came from remain distinct even after the cell becomes ... in the February 1 issue of Cancer Research. , ... quest to understand the causes of childhood brain cancers, according ... O. Schnuck Family Professor of Neurology at Washington University School ...
... that the risk of HIV transmission may be highest ... a study published in the April 1 issue of ... infection accounted for nearly half of all transmission occurrences ... Canada. , Bluma Brenner, PhD, and Mark Wainberg, PhD, ...
Cached Biology News:Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2
Competitors to lower non-specific signal...
... anti-rabbit IgG FITC is used as ... staining on tissues or culture cells ... in rabbits. It is highly recommended ... omitting the primary antibody, be included ...
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: